Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2008

View Archived Issues

Recent patent literature reports novel anticancer compounds

Yi-Gan San studied in dementia, tardive dyskinesia and borderline personality disorder

VaxGen and Raven terminate merger agreement

Cardiac-specific MAP kinase protects against cardiac ischemia in vitro and in vivo

Evotec and Ono sign agreement to identify compounds against a protease target

Encouraging results reported in first clinical trial of efficacy for GFT-505

Positive phase III data reported for new GnRH blocker degarelix

Avanir to raise gross proceeds of USD 40 million in a registered direct offering

MethylGene enters agreement with Otsuka for small-molecule kinase inhibitors

MPA requests additional information prior to initiation of Tripeps' ChronSeal phase II study

Thallion defers start date of phase II/III clinical trial of Shigamabs by six months

Evotec reports preliminary findings from study of EVT-101 in healthy volunteers

Seattle Genetics initiates second phase I clinical trial of SGN-35 in Hodgkin's lymphoma

New therapeutic agents for diabetic nephropathy described in recent Kowa patent

Recent Amgen and Kyowa Hakko patents disclose novel analgesic agents

IMPACT1 study demonstrates efficacy of Berinert P in hereditary angioedema

DJ-1 provides neuroprotection against oxidative stress

Effects on survival seen with EGF vaccine in non-small cell lung cancer patients

Lilly commences phase III LY-450139 trial for Alzheimer's disease

NeuroSearch initiates phase I NSD-788 study for anxiety and depression

Synosia Therapeutics commences phase II rufinamide trial for general anxiety disorder

Protectan CBLB-502 shows mitigation of hematopoietic damage post-radiation

UCB reports phase II results for CDP-791 in non-small cell lung cancer

Phase I/II trial in CF patients begins for Humaneered antibody against P. aeruginosa infections

NeoPharm enrolls first patients in phase II cancer trial of liposomal paclitaxel